SAFETY DATA SHEET

Fidaxomicin Formulation

SECTION 1. IDENTIFICATION

Product name : Fidaxomicin Formulation

Manufacturer or supplier's details
Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
          Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Acute toxicity (Oral) : Category 4

GHS label elements
Hazard pictograms : ![Warning]

Signal Word : Warning
Hazard Statements : H302 Harmful if swallowed.
Precautionary Statements : Prevention:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.

Response:
P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel unwell. Rinse mouth.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
</table>

1 / 14
SAFETY DATA SHEET

Fidaxomicin Formulation

SECTION 4. FIRST AID MEASURES

General advice:
In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled:
If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact:
Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact:
Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed:
If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed:
Harmful if swallowed.

Protection of first-aiders:
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician:
Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media:
Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media:
None known.

Specific hazards during fire fighting:
Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Carbon oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters:
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES
SAFETY DATA SHEET

Fidaxomicin Formulation

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spills cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labeled containers. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fidaxomicin</td>
<td>873857-62-6</td>
<td>TWA</td>
<td>200 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable)</td>
<td>5 mg/m³</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (total)</td>
<td>10 mg/m³</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (total)</td>
<td>15 mg/m³</td>
<td>OSHA Z-1</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
Fidaxomicin Formulation

<table>
<thead>
<tr>
<th>Engineering measures</th>
<th>Personal protective equipment</th>
</tr>
</thead>
</table>
| Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. | Respiratory protection: General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection. Hand protection:

Material: Chemical-resistant gloves

Remarks: Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection: Wear the following personal protective equipment:

Safety glasses

Skin and body protection: Skin should be washed after contact.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

<table>
<thead>
<tr>
<th>SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance: solid</td>
</tr>
<tr>
<td>Color: white to off-white</td>
</tr>
<tr>
<td>Odor: No data available</td>
</tr>
</tbody>
</table>
Odor Threshold : No data available
pH : Not applicable
Melting point/freezing point : 347 - 365 °F / 175 - 185 °C
Active ingredient
Initial boiling point and boiling range : Not applicable
Flash point : Not applicable
Evaporation rate : No data available
Flammability (solid, gas) : Not classified as a flammability hazard
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : No data available
Relative vapor density : No data available
Density : No data available
Solubility(ies) : Water solubility : No data available
Partition coefficient: n-octanol/water : log Pow: 4.4
Active ingredient
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : Not applicable
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY
SEASON 11. TOXICOLOGICAL INFORMATION

**Information on likely routes of exposure**

Skin contact
Ingestion
Eye contact

**Acute toxicity**

Harmful if swallowed.

**Product:**
Acute oral toxicity: Acute toxicity estimate: 833.33 mg/kg
Method: Calculation method

**Components:**

**Fidaxomicin:**
Acute oral toxicity: LD50 (Rat): > 1,000 mg/kg
LD50 (Dog): > 120 mg/kg
Acute toxicity (other routes of administration): LD50 (Rat): 200 mg/kg
Application Route: Intravenous

**Cellulose:**
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

**Starch:**
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

**Skin corrosion/irritation**
Not classified based on available information.

**Serious eye damage/eye irritation**
Not classified based on available information.
Components:

Starch:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Starch:
Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Fidaxomicin:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: Chromosome aberration test in vitro
  Test system: Chinese hamster ovary cells
  Result: positive

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Rat
  Application Route: Intravenous
  Result: negative

Cellulose:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
SAFETY DATA SHEET

Fidaxomicin Formulation

Species: Mouse
Application Route: Ingestion
Result: negative

Starch:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Cellulose:
Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Not classified based on available information.

Components:

Fidaxomicin:
Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Intravenous injection
Fertility: NOAEL: 6.3 mg/kg body weight

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 12.6 mg/kg body weight
Remarks: No significant adverse effects were reported

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 7 mg/kg body weight
Remarks: No significant adverse effects were reported

Cellulose:
Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat  
Application Route: Ingestion  
Result: negative

**Effects on fetal development**
Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**STOT-single exposure**
Not classified based on available information.

**STOT-repeated exposure**
Not classified based on available information.

**Repeated dose toxicity**

### Components:

**Fidaxomicin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>90 mg/kg</td>
<td>Oral</td>
<td>28 D</td>
<td>No significant adverse effects were reported</td>
</tr>
<tr>
<td>Rat</td>
<td>62.5 mg/kg</td>
<td>Intravenous</td>
<td>14 D</td>
<td></td>
</tr>
<tr>
<td>Dog</td>
<td>9,600 mg/kg</td>
<td>Oral</td>
<td>3 M</td>
<td>No significant adverse effects were reported</td>
</tr>
<tr>
<td>Monkey</td>
<td>90 mg/kg</td>
<td>Oral</td>
<td>28 D</td>
<td>No significant adverse effects were reported</td>
</tr>
<tr>
<td>Juvenile rat</td>
<td>200 mg/kg</td>
<td>Oral</td>
<td>28 D</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Cellulose:**

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>&gt;= 9,000 mg/kg</td>
<td>Ingestion</td>
</tr>
</tbody>
</table>
Starch:
Species: Rat
NOAEL: >= 2,000 mg/kg
Application Route: Skin contact
Exposure time: 28 Days
Method: OECD Test Guideline 410

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Fidaxomicin:
Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, constipation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity
Components:

Fidaxomicin:
Toxicity to algae/aquatic plants:
EC50 (Anabaena flos-aquae (cyanobacterium)): > 18.4 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Anabaena flos-aquae (cyanobacterium)): 5.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 8.91 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 19.6 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms:
EC50: > 50 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 5.9 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
**SAFETY DATA SHEET**

**Fidaxomicin Formulation**

**Version 3.4**

**Revision Date:** 10/10/2020

**SDS Number:** 1731985-00007

**Date of last issue:** 03/23/2020

**Date of first issue:** 06/05/2017

---

**Cellulose:**

Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

**Persistence and degradability**

**Components:**

**Cellulose:**

Biodegradability: Result: Readily biodegradable.

**Bioaccumulative potential**

**Components:**

**Fidaxomicin:**

Partition coefficient: n-octanol/water: log Pow: 4.4

**Mobility in soil**

**Components:**

**Fidaxomicin:**

Distribution among environmental compartments: log Koc: 0.80

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods**

Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION**

**International Regulations**

**UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.
SAFETY DATA SHEET

Fidaxomicin Formulation

Version 3.4  Revision Date: 10/10/2020  SDS Number: 1731985-00007  Date of last issue: 03/23/2020  Date of first issue: 06/05/2017

Domestic regulation

49 CFR
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards: Acute toxicity (any route of exposure)

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Fidaxomicin 873857-62-6
Cellulose 9004-34-6
Starch 9005-25-8

California Permissible Exposure Limits for Chemical Contaminants

Cellulose 9004-34-6
Starch 9005-25-8

The ingredients of this product are reported in the following inventories:

AICS: not determined
DSL: not determined
IECSC: not determined

SECTION 16. OTHER INFORMATION

Further information
NFPA 704:

<table>
<thead>
<tr>
<th>Health</th>
<th>Flammability</th>
<th>Instability</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® IV:

<table>
<thead>
<tr>
<th>HEALTH</th>
<th>FLAMMABILITY</th>
<th>PHYSICAL HAZARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>/ 1</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "***" represents a chronic hazard, while the "*/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH: USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL: USA. NIOSH Recommended Exposure Limits
OSHA Z-1: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA: 8-hour, time-weighted average
NIOSH REL / TWA: Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA: 8-hour time weighted average

AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantified...

Revision Date: 10/10/2020

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8